We have previously shown that stromal cell-derived factor-1α (SDF-1α) is downregulated within diabetic cutaneous wounds, and that direct application of recombinant SDF-1α increases wound closure rates, neovascularization, and endothelial progenitor cell (EPC) recruitment. However, increased wound levels of exogenous SDF-1α results in elevated systemic levels of this proangiogenic chemokine that raises concerns for tumorigenesis and inflammation. We now seek to test the efficacy of a novel, safer cell-based therapy (CBT) employing ex vivo primed bone marrow-derived stem cells (BMDSC) with SDF-1α. We also elucidate the mechanism of action of this new approach for accelerating diabetic wound healing. Methods: Unfractionated BMDSC from diabetic Lepr db/db mice were incubated for 20 hours with SDF-1α (100 ng/mL) or bovine serum albumin (control). Pretreated BMDSC (1 × 10 6 ) were injected subcutaneously into full-thickness skin wounds in Lepr db/db mice (n = 8 per group). Wound closure rates, capillary density, and the recruitment of EPC were assessed with serial photography, DiI perfusion, confocal microscopy, and immunohistochemistry. The expression of molecular targets, which may mediate prohealing/proangiogenic effects of SDF-1α-primed BMDSC was evaluated by polymerase chain reaction array and immunoblotting assay. The biological function of a potential mediator was tested in a mouse wound-healing model. Serum SDF-1α levels were measured with enzyme-linked immunosorbent assay (ELISA). Results: SDF-1α-primed BMDSC significantly promote wound healing (P < 0.0001), neovascularization (P = 0.0028), and EPC recruitment (P = 0.0059). Gene/protein expression studies demonstrate upregulation of Ephrin Receptor B4 and plasminogen as downstream targets potentially mediating the prohealing and proangiogenic responses. Ex vivo BMDSC activation and the subsequent inoculation of cells into wounds does not increase systemic SDF-1α levels.
T he past decades have heralded significant advancements in our understanding of stem cell biology and how it relates to tissue regeneration and repair. Recently, this vital knowledge has been at the forefront of intense investigation seeking to employ the high therapeutic potential of these pluripotent stem cells to create cell-based therapies that can target, and ultimately restore tissue/organ integrity. 1, 2 Delayed diabetic cutaneous wound healing is, perhaps, one of the most prevalent pathophysiological processes standing to benefit from such developing cell-based therapies. 3 Given that convincing evidence has demonstrated there to be a diabetes-associated reduction [4] [5] [6] [7] [8] [9] and dysfunction 4,10,11 of circulating bone marrow-derived stem cells (BMDSC), it stands to reason that the modulation of diabetic BMDSC to enhance their circulation, wound levels, and/or function could have significant clinical implications.
Numerous stem cell based therapies are currently being tested in the preclinical and clinical settings that are utilizing distinct subpopulations of BMDSC [ie, mesenchymal stem cells and endothelial progenitor cells (EPC)], in combination with various growth factors and signaling molecules, for numerous disease processes including diabetic wound healing. [12] [13] [14] [15] [16] [17] These immature BMDSC subpopulations have been shown to promote neovascularization and healing by direct cell-to-cell interactions, whereby they differentiate in situ into a variety of cell lineages, including fibroblasts, myoblasts, adipocytes, and mature endothelial cells, 1, 18 and they have also been shown to secrete numerous cytokines, growth factors, and extracellular matrix proteins that support the healing process in a paracrine manner. 3, [18] [19] [20] [21] Autologous transplantation of stem cell subpopulations, however, can present some limitations: (1) the small percentage of pluripotent mesenchymal stem cells and EPCs, respectively, that can be isolated, which would require the processing of large volumes of blood or bone marrow for adequate yield; and (2) the limitation of repeated cell passages and expansion, as these cells may undergo unfavorable changes in phenotype with time. 22 In line with these findings, the inherent reduction and dysfunction of diabetic BMDSC would only serve to intensify these limitations, thus making their clinical utilization more complicated. Nevertheless, BMDSC can be activated, or "primed," with a variety of chemokines, cytokines, and growth factors before their use to enhance their functional capabilities. [23] [24] [25] Specifically, the proangiogenic chemokine, stromal cellderived factor-1α (SDF-1α), which becomes highly expressed by numerous cell types during hypoxia (ie, after infarct, wounding), activates BMDSC by binding to the cell surface receptor CXCR4. 26 Accordingly, SDF-1α has been studied extensively in the context of BMDSC recruitment and neovascularization for a variety of reparative and pathological disease processes, [27] [28] [29] which in addition to wound healing, [30] [31] [32] [33] include tumorigenesis and metastasis, 34, 35 myocardial infarction 36 and restoration of blood flow in critical limb ischemia. 37, 38 Thus, it is well established that SDF-1α plays a crucial role in BMDSC activation, mobilization, and recruitment.
Our previous work has found that the local concentration of SDF-1α is markedly reduced in the diabetic wound. Moreover, we have demonstrated that by raising local tissue levels of SDF-1α with either exogenous administration of recombinant SDF-1α, or with virally transduced SDF-1α expressing bone marrow-derived fibroblasts, significant improvement in wound closure rate, neovascularization, EPC engraftment, and collagen deposition is achieved. 30, 31 As previously stated, however, elevated local tissue levels and/or increased systemic levels of SDF-1α have been implicated in tumorigenesis and metastasis. 34, 35 Indeed, mounting evidence continues to show that elevated systemic levels of SDF-1α, or increased expression of its receptor CXCR4, are strongly correlated with relapse, metastasis, and a worse prognosis in numerous neoplastic processes, including breast, gastric, prostate, and colon cancer. [39] [40] [41] [42] [43] [44] [45] In addition to cancer, elevated systemic or local expression of SDF-1α has also been linked with several inflammatory disease processes, including inflammatory liver disease, 46 lupus-induced nephritis, 47, 48 rheumatoid arthritis, and osteoarthritis. 49, 50 Thus, such highly effective and promising therapeutic approaches that function by directly, or indirectly, increasing the local expression/concentration of SDF-1α bring about challenges that may limit their clinical application.
To develop an effective and safe protocol for the treatment of diabetic wound healing, we explore the efficacy of a novel cellbased therapy utilizing SDF-1α-activated autologous bone marrow to promote diabetic wound healing. We sought to judiciously exploit the proangiogenic capabilities of SDF-1α, via ex vivo incubation, to mitigate any potential systemic effects. We postulated that in vitro incubation of unfractionated autologous BMDSC would activate these cells, enhancing their proangiogenic and prohealing capacity even after the removal of SDF-1α from the incubation media. Thus, we hypothesized that diabetic wounds treated with ex vivo SDF-1αprimed BMDSC would have a more robust healing response in line with our previous findings, and those of other investigators. 12, 30, 31, 51 That is, SDF-1α-activated BMDSC would promote better healing and increased neovascularity (ie, vessel density, EPC engraftment) compared with control diabetic wounds treated with nonactivated BMDSC. We then tested if ex vivo priming with SDF-1α increases endothelial cell-EPC interaction. Lastly, we explored the potential paracrine effect of plasminogen that may partially account for the accelerated wound healing observed in wounds treated with SDF-1α-primed BMDSC.
METHODS Mice
All animals were cared for in accordance with the guidelines set forth by the University of Miami Institutional Animal Care and Use Committee. Genetically diabetic male BKS.Cg-+ Leprdb/+ Leprdb/OlaHsd (Lepr db/db ) mice were obtained from Harlan Laboratories (Indianapolis, IN). All mice were used experimentally between 12 to 13 weeks of age. A total of 6 to 8 mice per treatment group were used. Before all procedures, serum glucose was measured from the tail vein using a glucometer. Mean serum glucose levels in all diabetic mice were 391 mg/dL with a range of 302 to 503 mg/dL. Animals had free access to food and water before and after the operation.
Bone Marrow Cell Harvest and Ex Vivo Treatment
Twenty-four hours prior to wounding experiments, diabetic donor mice (n = 4) were killed for bone marrow cell harvesting and fresh isolation of unfractionated BMDSC. The femurs and tibiae were carefully cleaned from surrounding soft tissue, and the distal epiphysis of each bone was removed using a sharp surgical micro scissor. The bone marrow was harvested by inserting a syringe needle (27-gauge) into one end of the bone and flushing with Dulbecco's Modified Eagle's Medium (Gibco). Mononuclear cells were counted, divided equally into 2 groups [(1) control (Bovine Serum Albumin) group; (2) SDF-1α treatment group), and plated on 10 mm cell culture dishes at a density of 1 × 10 7 /mL cells per dish in Dulbecco's Modified Eagle's Medium containing 10% Bovine Serum Albumin (Sigma-Aldrich), 100 u/mL penicillin (Sigma-Aldrich) and 100 u/mL streptomycin (Sigma-Aldrich). Control cells were treated with phosphate buffered saline + Bovine Serum Albumin (100 ng/mL); SDF-1α-primed cells were treated with murine SDF-1α (mSDF-1α, 100 ng/mL). Cultures were maintained at 37ÌC in a humidified atmosphere containing 95% air and 5% carbon dioxide for a period of 20 hours. After the 20-hour treatment period, cells were harvested, washed with 10 mL phosphate buffered saline × 3, and resuspended at a concentration of 1 × 10 7 /mL in phosphate buffered saline for the in vivo wounding arm of the experiment.
Surgical Procedures for Wounding and In Vivo BMDSC Wound Inoculation
For wounding experiments, diabetic mice (n = 8 per group) were anesthetized with an intraperitoneal injection of 80 mg/kg of ketamine and 20 mg/kg xylazine. Next, the dorsal surface was depilated. Under sterile conditions, one full-thickness excisional wound was created using an 8-mm punch biopsy on the mid back of each mouse, approximately 1 cm to the right of the mid-line exposing the pannus carnosus. The designated control wounds (n = 8) and SDF-1α wounds (n = 8) were then inoculated intradermally with control (Bovine Serum Albumin) treated cells or SDF-1α-primed cells (1 × 10 6 BMDSC cells/wound; 100 μL cell suspension/wound), respectively. In a subsequent wounding experiment, full-thickness wounds were created in a similar fashion. Mice were again separated equally into 2 groups (n = 6): (1) SDF-1α-primed cells (1 × 10 6 BMDSC cells/ wound) only, and (2) SDF-1α-primed cells plus plasminogen activator inhibitor-1 (1 × 10 6 BMDSC cells/wound) plus 10 μg/mL (effective dose of 1 μg/100 μL per wound) of plasminogen activator inhibitor-1 (plasminogen activator inhibitor-1: USBiological, Swampscott, MA). Plasminogen activator inhibitor-1 was administered intradermally to dorsal wounds with SDF-1α-primed BMDSC on postoperative day 0 and thereafter through postoperative day 5 (total dose 1 μg in 100 μL per wound per day).
Assessment of Wound Closure
Wounds were observed for 21 days, or until full closure, whichever came first. Digital photographs of the wounds were taken with a Canon digital camera at days 0, 3, 7, 10, 12, 16, and 20. Time to wound closure was defined as the time at which the wound bed was completely reepithelialized. Standard calibration of all wound surface area measurements was facilitated by the inclusion of a ruler in the photographs. Wound area was quantified using ImageJ software (Imaging Processing and Analysis in Java, National Institutes of Health, MD), and the wound closure or recovery rate was expressed as a percentage of the initial wound using the following equation: [(original wound area minus daily wound area) / (original wound area)] × 100. dothelium. Next, 10 mL of fixative (4% paraformaldehyde) was injected after the DiI perfusion, and the skin around the wound was excised for confocal microscopy to analyze the wound vessel density. The vascular network was visualized by scanning the entire wound tissue to a depth of 150 to 300 μm using laser scanning confocal microscopy (Leica MP/SP5/FCS/FLIM spectral multiphoton/confocal upright microscope, Leica Microsystems). Vessel density was quantified assessing the total number of red DiI-labeled vessels normalized to the entire scanned wound area with ImageJ software.
Immunohistochemistry, Immunostaining, and Immunoblotting
Immunostaining and immunohistochemistry were performed using 5-μm paraffin sections from the wounds of the perfused mice (vessels labeled with DiI) for the examination of EPC recruitment and capillary density. Paraffin-embedded sections first underwent standard de-paraffinization and rehydration procedures, and they were then probed with fluorescein isothiocyanate-anti-CD34 (Cell Signaling Technology, Danvers, MA) for keeping overnight at 4 • C. Next, sections were incubated with horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology Inc, Santa Cruz, CA). The nuclei were then counterstained with 4', 6-diamidino-2phenylindole, dihydrochloride. Negative controls for all antibodies were made by replacing the primary antibodies with nonimmunogenic, isotype-matched antibodies from the same manufacturer. Tissue sections were analyzed using fluorescence microscopy and Im-ageJ software to quantify fluorescent intensity. Hematoxylin and eosin staining was performed according to standard methods for the assessment of epithelialization.
Immunoblotting was performed as previously described. 30 Briefly, unfractionated BMDSC were lysed, and protein concentrations were determined by Detergent-compatible TM protein assay (Bio-Rad). Equal amounts of protein were subjected to 4% to 12% sodium dodecyl sulfate gel electrophoresis under reducing conditions and transferred to polyvinylidene fluoride (PVDF) membranes. The transferred PVDF membranes were subsequently probed with antibodies to Plasminogen (Abcam, Cambridge, MA), Ephrin Receptor B4 (Santa Cruz Biotechnology Inc, Santa Cruz, CA) or β-actin (Abcam, Cambridge, MA). Membranes were then probed using horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology Inc, Santa Cruz, CA) and subjected to enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ). Membranes were stripped and reblotted as required for each experiment.
Polymerase Chain Reaction Array
Two quantitative polymerase chain reaction arrays were performed: (1) the Mouse Wound Healing RT 2 Profiler polymerase chain reaction Array (Qiagen, Valencia, CA), which quantitatively profiles the expression of 84 genes central to the wound healing process. For this array, unfractionated BMDSC were stimulated with recombinant SDF-1α protein (100 ng/mL) versus Bovine Serum Albumin (100 ng/mL) for 20 hours; (2) the human adhesion molecules and extracellular matrix RT 2 profiler polymerase chain reaction array, which quantitatively profiles the expression of 84 genes of adhesion molecules and extracellular matrix (PA-011, SABiosciences, Frederick, MD) was performed as previously described. 31 All cells were harvested and total ribonucleic acid (RNA) was extracted using Trizol (Invitrogen). Synthesis of complementary DNA was then performed using RT 2 First Strand Kits (Qiagen, Valencia, CA). Polymerase chain reaction array was carried out in accordance with the manufacturer's protocol. The threshold cycle values were used to plot a standard curve. All samples were normalized to the relative levels of β-actin, and the results were expressed as fold-increase. The threshold for in-creased gene expression was designated as one fold or more increase in messenger RNA (mRNA) for all experiments.
MTT Proliferation Assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Cell Proliferation Assay (Roche Applied Science, Indianapolis, IN) is an in vitro assay for the measurement of cell proliferation. MTT assay was performed in accordance with the manufacturer's protocol on harvested unfractionated Lepr db/db BMDSC 20 hours after ex vivo incubation with Bovine Serum Albumin (100 ng/mL) or SDF-1α (100 ng/mL), respectively, to determine any alterations/changes in cell proliferation between control (Bovine Serum Albumin) and SDF-1α-primed BMDSC.
Apoptosis Assay
The difference in cell apoptosis between BMDSC treated with Bovine Serum Albumin (100 ng/mL) versus SDF-1α (100 ng/mL) was determined using flow cytometry. After 20-hour incubation with either Bovine Serum Albumin or SDF-1α, apoptosis was determined using a fluorescein isothiocyanate-conjugated annexin-V propidium iodide kit (Abcam Inc, Cambridge, MA) according to the manufacturer's instructions.
Enzyme-Linked Immunosorbent Assay
Mouse serum SDF-1α concentration analysis was performed 24 hours after wounding procedure using Quantikine SDF-1α ELISA kit (DY460, R&D Systems), which specifically detects murine SDF-1α, based on the manufacturer's protocol.
Data Processing and Statistics
In vivo histology data were analyzed using ImageJ software. Histological images were taken from multiple sections (at least 8 sections per sample) and the wound edges were determined using the position of the first hair follicle. P values were calculated for the indicated groups by using a 2-tailed Student t test.
RESULTS

Ex Vivo SDF-1α Treatment of Diabetic Bone Marrow Cells Enhances Proliferation Rate, But Does Not Alter Cell Viability
We have previously shown that the direct inoculation of diabetic wounds with recombinant SDF-1α causes a transient increase in systemic levels of SDF-1α. 30 We attempted to limit any potential systemic exposure to SDF-1α by treating the selected cell population ex vivo before diabetic wound treatment. Unfractionated, freshly isolated BMDSC harvested from Lepr db/db mice were treated with Bovine Serum Albumin versus SDF-1α (100 ng/mL) for 20 hours. The effects of SDF-1α on cell apoptosis and proliferation were examined using flow cytometry and MTT, respectively. Cells in the SDF-1α treatment group and the control (Bovine Serum Albumin) treatment group were equally viable after the 20-hour treatment period ( Figs. 1A-B ). In comparison, the proliferation rate of SDF-1αactivated cells was enhanced fourfold (P < 0.001) when compared with control cells (Fig. 1C ). Using an in vitro adhesion assay, we observed that ex vivo priming with SDF-1α significantly increases the direct interaction of mature endothelial cells with the EPC subpopulation of the primed BMDSC (endothelial cell-EPC adhesion data not shown). jected into diabetic wounds created on the dorsal skin of Lepr db/db mice. To determine whether SDF-1α treated BMDSC exhibit any effect on endogenous SDF-1α levels after wound inoculation, serum was collected from mice in each treatment group 24 hours after wounding and cell inoculation procedure. Systemic SDF-1α levels were analyzed using ELISA. There was no significant difference in systemic levels of SDF-1α between the control group and the SDF-1α treatment group 24 hours after inoculation into the wounds (Fig. 2) . Thus, the cell-based therapy utilized for these experiments was successful in minimizing systemic exposure to recombinant SDF-1α.
Direct Inoculation of Diabetic Wounds With SDF-1α-Primed BMDSC is an Effective Cell-Based Therapy Promoting Diabetic Wound Healing and Neovascularization
Our previous work has established the significant prohealing effects of SDF-1α in the diabetic wound with respect to EPC mobilization and recruitment/adhesion to the wound bed. 30 The purpose of this study was to test the efficacy of a novel cell-based therapy using autologous, unfractionated BMDSC activated ex vivo with SDF-1α in a genetic murine model of type 2 diabetes mellitus. Diabetic cutaneous wounds treated with ex vivo SDF-1α-activated BMDSC had a significantly faster healing rate when compared with wounds treated with control BMDSC (Fig. 3A) . The most significant difference was observed during days 7 to 12 (1.8-fold difference in wound closure observed starting on day 9). Wounds were harvested and subjected to Hematoxylin & Eosin to assess for epithelialization. Hematoxylin & Eosin staining showed incompletely healed wounds for the control group, which were inoculated with Bovine Serum Albumin-stimulated BMDSC cells compared with completely healed wounds that were inoculated with SDF-1α-stimulated BMDSC cells ( Fig. 3C ). Wounds were harvested and subjected to immunohistochemistry analysis after DiI in vivo perfusion to assess for the recruitment of EPC-like cells (CD34 + /DiI + cells) within the vascular network. EPC engraftment (Figs. 4A-B) was significantly greater in wounds treated with SDF-1α-activated BMDSC cells when compared with control wounds treated with Bovine Serum Albumin BMDSC. In addition, wound vessel density was significantly greater (fourfold increase) in the diabetic wounds treated with SDF-1αactivated BMDSC, as assessed by DiI in vivo perfusion and confocal microscopy at the time point examined (day 20) (Figs. 4C-D). These data provide evidence corroborating the prohealing and proangiogenic influence of BMDSC activated ex vivo with SDF-1α in a murine model of type 2 diabetes mellitus.
SDF-1α UpRegulates Expression of Plasminogen (and Numerous Adhesion Molecule Changes) in Diabetic Unfractionated BMDSC
To study potential downstream mechanisms whereby SDF-1α ex vivo priming potentiates the wound healing response of BMDSC, we performed RT 2 polymerase chain reaction to analyze specific genes, upregulated by SDF-1α, that are important to the wound healing response. In total, 84 genes involved in the 3 critical phases of wound healing were assessed. Of the 84 genes analyzed, there was an upregulation of 4 genes (>1.2-fold; Table 1 ). We focused on 2 genes consistently upregulated with SDF-1α stimulation in diabetic BMDSC, which are involved in the remodeling/angiogenesis phase of wound healing ( Fig. 5A ): Plasminogen and Epherin receptor B4. Further validation of the observed gene expression studies with western blot analysis confirmed a corresponding increased protein expression of plasminogen (2.9-fold increase) and Epherin receptor B4 (1.4fold increase) ( Fig. 5B) . These experiments identified plasminogen as one potential clinically relevant target that may contribute to the prohealing effects of SDF-1α-activated BMDSC and we performed additional in vivo studies on this target. Gene expression studies also demonstrated numerous adhesion molecules strongly expressed in BMDSC with SDF-1α priming, including integrin α4 and integrin αV (data not shown).
Plasmin Activator Inhibitor-1 Partially Abrogates the Prohealing Effects of SDF-1α-Primed BMDSC
To investigate whether upregulated levels of plasminogen in SDF-1α-activated BMDSC are contributing to the enhanced wound healing rates and/or neovascularization observed in diabetic cutaneous wounds, we performed additional in vivo wounding experiments using the specific plasminogen/plasmin antagonist, plasminogen activator inhibitor-1. Plasminogen activator inhibitor-1 is the key regulator of plasminogen to plasmin conversion; plasmin is a fibrinolytic enzyme implicated in angiogenesis and tissue remodeling. Wounds concurrently treated with plasminogen activator inhibitor-1 and SDF-1α-activated BMDSC had significantly slower healing rates than those only treated with SDF-1α-activated BMDSC at one time point, postoperative day 12 ( Fig. 6A ; P = 0.0035). However, a similar percentage of healing rates was observed for all other time points between the 2 groups. Capillary density, as determined by DiI, showed a trend toward reduction after concurrent treatment with plasminogen activator inhibitor-1 and SDF-1α-activated BMDSC versus only SDF-1α-activated BMDSC, but this trend did not reach a statistically significant difference at the time point examined, postoperative day 20 ( Fig. 6C and Fig. 6D ; P = 0.092). EPC numbers were equivalent in both groups in correspondence with the similar vessel densities observed between groups (data not shown). These findings suggested that plasminogen inhibition with plasminogen activator inhibitor-1 did not have a pronounced effect on the wound healing and proangiogenic effect of SDF-1α-Primed BMDSC.
DISCUSSION
In this work, we have demonstrated an innovative and efficacious cell-based therapy that safely harnesses the vital proangiogenic/prohealing characteristics of SDF-1α essential for diabetic cutaneous wound healing. We show that diabetic wounds inoculated with autologous SDF-1α-primed BMDSC have markedly improved wound closure rates, wound neovascularization, epithelialization and significantly increased numbers of EPC compared with control diabetic wounds treated with control BMDSC. Notably, the donor mice used to obtain the BMDSC were genetically diabetic and hyperglycemic similar to the recipient mice. The experimental conditions were selected to maximize relevance to a potential autologous cell-based therapy clinical protocol. Furthermore, this study investigated the possible role of the plasminogen/plasmin cascade in SDF-1α-mediated diabetic wound neovascularization and wound healing.
In this most current investigation, a genetic murine model of type 2 diabetes (Lepr db/db ) was used, and, like diabetic patients, Lepr db/db mice displayed impairments in wound healing, wound granulation tissue formation, and angiogenesis. 51, 53, 54 We found a nearly twofold increase in the wound closure rate between the SDF-1α-/BMDSC-treated wounds and the control treated wounds starting on postoperative day 9, and the wound closure rate remained significantly greater from postoperative day 9 until the end of the experiment (postoperative day 20). What is more, a significantly higher percent of SDF-1α-treated wounds were completely healed on postoperative day 20 compared with control wounds (93% vs 61%; P < 0.001). Such a marked difference in healing rates was not expected. That is, because both wounds were being treated with unfractionated BMDSC, a less profound difference had been anticipated. This may point to the inherent decreased repair functions of diabetic BMDSC.
To assess whether the differences in wound closure rates observed could be accounted for by a disparity in cell viability with ex vivo cell manipulation, viability (apoptosis) and proliferation assays were performed to determine a potential SDF-1α-mediated cell survival advantage. SDF-1α treatment did not elicit a specific cell survival advantage; however, the proliferation rate of SDF-1α-treated BMDSC was approximately fourfold greater than control treated cells. Thus, SDF-1α-activated cells and control cells were equally viable at inoculation (after ex vivo priming), but the proliferation rate of cells primed with SDF-1α was markedly enhanced. The utilization of unfractionated BMDSC precluded us from determining which bone marrow cell subtypes were induced to proliferate with SDF-1α treatment. Nevertheless, these findings lead us to speculate that SDF-1α-induced diabetic BMDSC proliferation enables a more immediate and more effective participation of these cells in the wound healing process (ie, wound re-epithelialization and neovascularization).
Impaired wound healing in diabetes may be a consequence of several factors, including deficient neovascularization. [55] [56] [57] Although problem diabetic wounds result, in part, from impaired neovascularization, the complexity of this process is still being defined. Our previous work has established a strong correlation between the diabetic phenotype and the significant downregulation of SDF-1α in diabetic cutaneous wounds resulting in deficient EPC recruitment, impaired neovascularization, and delayed healing. 30 Here, our novel cell-based therapy demonstrates that wounds inoculated with diabetic SDF-1α-primed BMDSC have significantly faster healing rates and enhanced neovascularization than wounds treated with diabetic control BMDSC. Numerous studies demonstrate that BMDSC contribute to the repair and regeneration of various tissue types, including blood vessels, 27,58 myocardium, 36 bone, 59 cartilage, 60 and skin. 61 With respect to the skin in particular, these stem cells have been found in the healing wound directly contributing to different cell types, such as keratinocytes, epithelial cells, and endothelialcell. [61] [62] [63] [64] In addition to their differentiation potential, BMDSC have also been shown to elaborate specific cytokines integral to skin repair and neovascularization. 63, 65 Thus, these cells have the capability of directly and/or indirectly (paracrine effect) participating in the healing response. Our findings strongly support the direct participation of BMDSC in wound healing and indicate that SDF-1α-mediated cell activation is critically involved in contributing to diabetic wound neovascularization and healing, because we observed increased numbers of EPC-like cells incorporated into the neovascular network of wounds treated with SDF-1α-primed BMDSC.
EPC are a heterogeneous and unstable population of cells. To date, there is no standard set of surface markers that definitively identify the EPC. Markers used to identify these cells vary widely depending on the species under study (eg, AC133 only pertains to human EPC whereas SCA-1 is a more reliable antigen for murine EPC). Currently, there is no consensus on the best combination of cell surface markers to describe the EPC. Instead, a combination of coexpressed markers is used to describe them. In many studies, one earlier marker (AC133, CD34, or Sca-1) plus one endothelial cellspecific marker, such as VEGFR2/KDR, CD31, are widely used to define EPC. CD34, in particular, is selectively expressed within the human and murine hematopoietic systems on stem and progenitor cells, [66] [67] [68] and it has been widely used to define EPC in a variety of studies. 23, [69] [70] [71] [72] In our investigation, we used a combination of CD34 (an early marker mainly expressed on hematopoietic stem cells and EPCs) and uptake of fluorescent DiI-labeled acetylated low density lipoprotein, which is known to be a specific characteristic of mature ECs, to define CD34+/DiI+ cells as EPC-like cells that present within the wound neovascular network.
Indeed, our most current findings are congruent with our previous work demonstrating the critical role of SDF-1α-mediated expression of endothelial cell expressed E-selectin, an adhesion molecule promoting endothelial cell-EPC interaction, in diabetic cutaneous wounds. 31 Thus, we explored the SDF-1α-mediated upregulation of other adhesion molecules expressed within the EPC subpopulation that could shed new light on our findings. Gene expression studies outlined numerous EPC adhesion molecules (data not shown) strongly expressed in the presence of SDF-1α, including integrin α4 and integrin αV, which are intricately involved in angiogenesis, vasculogenesis, and vascular remodeling. 27, [73] [74] [75] Findings from an in vitro assay of endothelial cell-EPC adhesion after SDF-1α ex vivo priming (data not shown) also implicates adhesion molecules as downstream effectors of the cell-mediated prohealing and/or proangiogenic effects. Thus, we observed further evidence to suggest that SDF-1α promotes the engraftment of EPC into the neovasculature of diabetic wounds, potentially by facilitating endothelial cell-EPC interaction. However, EPC represent a small proportion of BMDSC (<1% of all nucleated cells), and the dramatic enhancement of wound vessel density and re-epithelialization in SDF-1α-treated wounds likely supports the participation of additional cell subpopulations and coexisting paracrine mechanisms. Thus, the role of adhesion molecules in this type of cell-based therapy is highly complex and will require a separate, future dedicated study. FIGURE 6. Inhibition of the Plasminogen/Plasmin axis by plasminogen activator inhibitor-1 mildly reverses the wound healing and wound vessel density effects of SDF 1α-primed BMDSC. A, Wound healing rate expressed as a percentage of recovery. Two groups of type 2 diabetic Lepr db/db mice were wounded and treated with [ex vivo SDF-1α-activated diabetic BMDSC (labeled as SDF 1α)] versus plasminogen activator inhibitor-1 plus ex vivo SDF-1α-activated diabetic BMDSC (labeled as PAI+)]. Wounds were followed and analyzed using digital photography and ImageJ software. Diabetic wounds in the PAI+ group had mildly prolonged wound closure rate compared with wounds treated only with SDF-1α-activated BMDSC. A statistically significant delay in wound closure was noted between postoperative day 9 through postoperative day 12. B, Representative images of wounds at different time points are shown for both groups. C, Wound blood vessel perfusion as detected by DiI dye; images acquired using laser scanning confocal microscopy show DiI-stained blood vessels within the diabetic wounds, at day 21 post wounding. D, Quantification of vessel density in the wounds expressed as the percentage of threshold area, which covers all vessels detected as a percentage of the entire wound area. SDF-1α treated wounds showed a trend toward less vessel density compared with PAI+ treated wounds, but the means did not reach statistical significance. Data are presented as mean ± standard deviation of 6 wounds in each group.
With respect to a potential paracrine mechanism, we examined downstream targets influenced by SDF-1α activation that could potentially be influencing the prohealing response observed in vivo. We first performed gene expression studies to isolate the key downstream targets upregulated by SDF-1α, which are integral to the wound healing process. Two of the key genes consistently upregulated were EpherinB4 and Plasminogen. In this work, we focused our efforts on Plasminogen based on prior evidence implicating the Plasminogen/Plasmin cascade in angiogenesis, and in disrupted wound healing. [76] [77] [78] [79] [80] [81] Plasminogen is the inactive proenzyme form of Plasmin, a serine protease that is highly regulated and widely involved in extracellular matrix proteolytic activity. 76 Although the major physiological function of this system is fibrinolysis to maintain vascular patency, a number of studies have implicated Plasminogen/Plasmin in facilitating cell migration via direct proteolysis of extracellular matrix proteins, or, indirectly, by activation of other matrix degrading pathways (eg, metalloproteases). These proteolytic events are pivotal in wound healing, tissue remodeling, and angiogenesis. 76, 82, 83 The primary inhibitor of Plasminogen to Plasmin conversion is plasminogen activator inhibitor-1. Physiological levels of plasmino-gen activator inhibitor-1 serve to balance the degradative capability of Plasminogen/Plasmin. Various growth factors mediate temporal changes in the expression of plasminogen activator inhibitor-1 and its target, plasminogen activators (ie, u-PA, t-PA), thereby influencing cell migration by barrier proteolysis and/or extracellular matrix adhesion modulation. 84 Interestingly, low levels of plasminogen activator inhibitor-1 expression, leading to increased Plasminogen, has been associated with accelerated wound healing, angiogenesis, fibrinolysis, and bleeding. 80, 85, 86 Conversely, elevated plasminogen activator inhibitor-1 expression, leading to decreased Plasminogen, has been associated with obesity, atherosclerosis, hypercoagulability, and, inconsistently, with delayed wound healing responses in diabetes. 81, [86] [87] [88] [89] We performed in vivo wounding experiments to more precisely determine what specific role, if any, the upregulation of Plasminogen was having on the enhanced wound closure rates and neovascularization observed among the diabetic wounds treated with SDF-1α-primed BMDSC. We locally administered a supraphysiological, antiangiogenic dose of recombinant plasminogen activator inhibitor-1 (total dose of 1 μg in 100 μL) 79 to diabetic wounds for 5 consecutive days to ensure adequate inhibition of the Plas-minogen/Plasmin enzymatic axis. Diabetic wounds inoculated with SDF-1α-Primed BMDSC and blocked with concurrent plasminogen activator inhibitor-1 injections (SDF-1α/plasminogen activator inhibitor-1) did not appear grossly different from the wounds treated with only SDF-1α-activated cells at any time point during the experiment. The only difference appreciated was a mildly prolonged wound closure rate in the SDF-1α/plasminogen activator inhibitor-1 group that reached statistical significance during postoperative day 9 through postoperative day 12 time points (the most critical time interval during which the largest difference in wound healing was observed in all in vivo wounding experiments). Nevertheless, nearly all mice in the SDF-1α/plasminogen activator inhibitor-1 group achieved complete closure of wounds by postoperative day 20 in similar fashion to mice treated with SDF-1α-activated cells, albeit over a slightly more protracted time course. In correlation with the fairly similar wound closure rates appreciated between the 2 groups, wound vessel density and EPC-like cell numbers did not reach a statistically significant difference (vessel density P = 0.092; EPC data not shown) at the time point examined (postoperative day 20), although vessel density did appear to trend down in the SDF-1α/plasminogen activator inhibitor-1 group. These modest inhibitory effects of plasminogen activator inhibitor-1 point to other downstream mediators (in addition to Plasminogen/Plasmin) as effectors of the SDF-1α-primed BMDSC prohealing and proangiogenic effects, likely candidates being adhesion molecules, as discussed earlier. Alternatively, redundant pathways within the Plasminogen/Plasmin enzymatic cascades may account for the observed modest inhibitory effects.
Previous data suggest that the matrix metalloproteinase family of enzymes can perform the necessary proteolytic functions essential for wound healing and angiogenesis when the Plasminogen/Plasmin cascade is deficient, and that inhibition of both proteolytic pathways, in turn, severely impairs wound healing. 83 Thus, there exists functional overlap between tissue degrading proteases, which are involved in re-epithelialization, extracellular matrix deposition/extracellular matrix turnover, and neovascularization. Such functional overlap could relate to the similarity in wound healing and neovascularization observed between the SDF-1α and SDF-1α/plasminogen activator inhibitor-1 groups. Other possibilities to explain the similar findings could relate to the time points during which plasminogen activator inhibitor-1 was administered, or to the in vivo half-life of plasminogen activator inhibitor-1, or to the distribution of the protein within the wound tissue. Lastly, the chosen time point during which wounds were harvested may have diluted the biological effect because the effects of Plasminogen inhibition may have diminished by day 20. Nevertheless, the fact that a significant difference in wound healing was observed between groups from postoperative day 9 through postoperative day 12 suggests that Plasminogen is, indeed, partially involved in the healing response mediated by SDF-1α-activated BMDSC. Yet, the local and compensatory upregulation of other extracellular matrix degrading proteases, and the potential concurrent or collaborating role of adhesion molecules involved within diabetic wounds treated with SDF-1α-activated BMDSC, will require further verification.
CONCLUSIONS
Our data provide strong preclinical evidence for the potential utility, safety, and efficacy of ex vivo SDF-1α activation of BMDSC for the ever increasing unsolved problem of delayed diabetic cutaneous wound healing. Furthermore, we provide insight into the biological enhancement of diabetic wound neoangiogenesis and reepithelialization that may be mediated, in part, by SDF-1α upregulation of the Plasminogen/Plasmin cascade within the BMDSC population. We also shed light on other potential targets within the BMDSC subpopulations that might be enhancing the engraftment of EPC within diabetic wounds inoculated with SDF-1α-Primed BMDSC (ie, some specific adhesion molecules). Most importantly, however, the ex vivo priming of BMDSC with SDF-1α may offer the opportunity to enhance the efficacy of numerous cell-based therapies seeking to employ the tissue regenerating capabilities of BMDSC for the unsolved clinical problem of delayed diabetic cutaneous wound healing. Indeed, this novel cell-based therapy could easily be incorporated into new translational platforms for future clinical trials, the clinical implications of which could be far reaching.
DISCUSSANT
DR. LOUIS MESSINA (Worcester, MA): Dr. Castilla has reported the results of a potentially important preclinical study of autologous transplantation of SDF-1α-activated bone marrow mononuclear cells to reverse the impaired wound healing phenotype in an experimental model of type-2 diabetes in the leptin receptor knockout db/db mouse.
Although debate persists about the identity of endothelial progenitor cells, strong evidence from both preclinical and clinical studies in diabetics have shown that endothelial progenitor cells can promote therapeutic angiogenesis. However, very few studies have been undertaken in diabetic models, such as that presented today, especially utilizing autologous transplantation.
If the bone marrow strategy reported today can be reproduced in humans, and thereby provide an effective strategy for diabetic foot ulcers, it would address a major public health imperative.
As Dr. Castilla indicated, diabetic foot ulcers are one of the most common complications in diabetes, occurring in up to 25% of patients. 85% of lower limb amputations that diabetics undergo are preceded by a diabetic foot ulcer, with costs associated with such procedures at $86 billion a year.
This study tested the hypothesis that autologous transplantation of ex vivo SDF-1α-activated bone marrow mononuclear cells promotes a higher rate of wound healing in type-2 diabetic mice by engraftment of EPCs that increases wound neovascularization.
Chemokine-12, also known as stromal derived factor 1, exists as two alternative spliced variants, SDF-1α and SDF-1αβ. SDF-1α is constitutively expressed by bone marrow and other cells, including mesenchymal stem cells, from which they derive their names, and are powerful chemoattractants for hematopoietic stem cells and a variety of inflammatory and immune cells.
Key findings of this study were that autologous transplantation of SDF-1α-activated bone marrow mononuclear cells increased the rate of wound healing in type-2 diabetic mice by nearly twofold, and vessel density by fourfold, that the authors postulated is related to increase endothelial progenitor cell/adult endothelial cell interaction. It was unclear to me how the CD34 expression on endothelial cells distinguished between donor and recipient EPCs, or endothelial cells.
The relationship of this rate of wound healing to that in wild type mice was not provided. To obtain insight into the potential molecular mechanisms, they showed Ephrin B4 and plasminogen expression were increased, but subsequent experiments failed to document that plasminogen-induced matrix proteolytic activity was essential to the increased rate of healing.
The strength of this cell-based therapy is its simplicity of acquisition and preparation. But this simplicity also leaves open the intriguing question as to which bone marrow mononuclear cell population and by what mechanism does it achieve this increased rate of wound healing.
Because of the negative results of the PAI experiments, we are left with little mechanistic insight into these remarkable results that may soon have applicability to treat diabetic foot ulcers in humans.
I have two questions.
The study showed SDF-1α activated bone marrow increased mononuclear cell proliferation. My lab and others have shown that EPC function and capacity to mobilize in response to induction of ischemia is impaired in db/db mice. Have you determined the effect of SDF-1α on the function of endothelial progenitor cells or any other bone marrow mononuclear cell population?
Second, to better understand the relative contribution of the diabetic environment versus diabetes-induced progenitor cell dysfunction, have you performed experiments to determine the effect on wound healing after transplantation of bone marrow donor cells from wild type mice into diabetic recipient mice and db/db diabetic bone marrow cells into wild type recipients?
CLOSING DISCUSSANT
DR. OMAIDA VALEZQUEZ: Addressing three of your key comments first, in regard to how the CD34 stains could differentiate between donor versus recipient, the donor cells were labeled with DiI (red) or green fluorescent protein (GFP) in various experiments. So the double positive stain (the pre-injection label as well as the CD34 stain), would then identify those cells as the injected transplanted treatment cells.
In regard to the comment on the negative results for the PAI experiments, we believe that has to do with the fact that we chose a time point of post-wounding day 20 for wound tissue analysis. The PAI was given in the first five days after the injection of the cells. And then, those wounds were harvested at post-wounding day 20, so we have missed the window to demonstrate the role of Plasminogen in the early pro-angiogenic effects. So, although we saw a trend towards an inhibition of the angiogenic effect on day 20 by the early PAI injections, it was not statistically significant. However, the wound healing experiment was positive, indicating a significant inhibition effect with PAI. We saw a significant inhibition of the wound healing with the PAI at around day nine. And so, on that particular experiment, we have an indication that Plasminogen, at least in part, may, in fact, be mediating the pro-repair effects of the SDF-1• ex-vivo activation. Additionally, we believe that the mechanisms of action here include multiple cell types and multiple cytokines, as well as several adhesion molecules (e.g. E-Selectin, integrin alpha 4, VCAM).
Lastly, in regard to your comment on the population or cell type that is involved, I think we are going to end up having to do a number of other studies. Certainly, we believe that at least one cell type that is important is the endothelial progenitor cells (EPC), but those constitute a small faction of all of the mononuclear bone marrow cells that are being implanted. So there's probably several other cell types involved.
Going on to your two specific questions, in regard to whether SDF-1o affects not only the proliferation of these bone marrowderived stem cells but also the function, we have evidence that suggests that it is specifically impacting the adhesion molecule profile on the surface of the bone marrow-derived cells, specifically adhesion molecules like E-selectin, such as VCAM and integrin alpha 4. And when we do further studies, we show that not only are those molecules changed on the surface of the cells, but SDF-1• is specifically regulating the direct adhesion forces of the endothelial progenitor cells (EPC) to mature endothelial cells (EC) in our in vitro assays.
On in vivo experiments, all that we know is that the pro-repair in vivo capacity of these diabetic bone marrow-derived cells, that are activated ex vivo by SDF-1•, appears to be more robust. So to that extent, we do believe that the function of these cells is being altered by SDF-1•, although we are probably going to have to do more indepth experiments in that area (to specifically determine what biologic functions are most significantly affected).
DISCUSSANT
DR. CRAIG KENT (Madison, WI): One of the things that I really enjoy about your studies with SDF-1 alpha is that you are almost ready to translate... and this is the focus of my question.
You have worked with SDF-1α in diabetic wounds for a number of years. You've put the SDF-1α directly in the wound. And then you transfected SDF-1α into fibroblasts, and put the fibroblasts in the wound. Today you present a third iteration, where you are stimulating bone-marrow derived cells ex vivo with SDF-1α and then putting the bone-marrow derived cells into the wound.
Could you give us some sense of the comparative efficacy of those three different approaches? Does one work better than another? I realize that you don't like the first two approaches because you are worried about raising systemic levels of SDF-1α, but my question is whether your new approach with bone marrow cells is as effective as the other two techniques that you have used.
The second question is about the proliferation. SDF-1α stimulates proliferation of these bone-marrow derived stem cells. Maybe the whole effect that you have observed is related to having increased the number of bone marrow stem cells by ex vivo exposure to SDF-1α. So the reason there is a positive response with the SDF-1α treated cells is that there are just more cells being applied to the wound. The caveat would be that if you could find anything that would stimulate proliferation of these cells and ultimately put more cells in the wound, you would have the same beneficial effect.
CLOSING DISCUSSANT
DR. OMAIDA VALEZQUEZ: It has been, as you mention, an extensive work, that led from the understanding as to whether the SDF-1• played any role whatsoever in diabetic wound healing, to some of the mechanisms where it may actually be working, to now how could it be used in a potentially safe preclinical platform. And ultimately, exactly, our goal is to be able to bring it to a clinical testing platform.
To answer your first question, what is the difference between direct SDF-1• application and ex vivo activation of bone marrow cells? And they are all effective in the sense that the rate of wound closure is improved. But direct application of the ex vivo activated bone marrow cells carries significant advantages.
The wound healing rates are as good, and sometimes, in some of the experiments, much better (with the novel cell base therapy described). But the systemic spillage of increasing the baseline level of serum SDF-1• is nonexistent with ex vivo cell activation, which is a great advantage. And by injecting the cells, as opposed to a single cytokine, we get the effects of cytokine cell activation plus we get the cells delivering a number of other cytokines (which we don't quite understand yet) plus cell-cell functions that we know from parallel clinical trials can lead to very positive pro-healing and pro-angiogenic effects that increases limb salvage.
So we believe this latest iteration is probably the most effective, and likely the safest one that we could potentially push onto a clinical testing platform.
And then, in regard to the effect on proliferation and the cell number issues, we know, from our experiments, that the ex vivo activation with SDF-1• was done first. And then, the number of cells injected per wound was standardized. So it was a million cells into each of the wounds. Whatever the proliferative effect that took place during the ex vivo activation process, it's not immediately the cause of the effects.
Of course, one could also potentially deduce that maybe the cells, when injected, continue to proliferate at a higher rate, and that all of the beneficial effects have to do with a faster proliferating cell group. However, the gene expression profiles that we've done, identifying some adhesion molecules and some proteolytic cascades, such as the Plasminogen to Plasmin cascade, suggest to us that it's more complex than just a cell number effect. That, in fact, we are dealing now with a potential treatment protocol that carries a number of synergistic pro-wound-healing effects into the diabetic wound phenotype.
DISCUSSANT
DR. ADRIAN BARBUL (Hackensack, NJ): I have two questions.
SDF-1's main ligand is CXCR4. Have you done any work using an agent such as AMD 3100 to block the receptor and see if you get a similar effect? This would explain the mechanism of action on the EPC cells that you treated ex vivo?
Second, I want to raise a point of caution, namely that transplanting cells within wounds can be very dangerous. Dr. Stanley Levenson, a longstanding member of this society who recently passed away, did an experiment about 40 years ago, transplanting wound fibroblasts into freshly created wounds, and reported great success in enhancing wound healing. Several animals survived out to six months and all developed sarcomas.
So I would raise the caution that perhaps you need to do longterm studies on how these animals behave long term, to make sure that indeed you can use the words "safe therapy" in such a transplantation model. 
Copyright
CLOSING DISCUSSANT
DR. OMAIDA VALEZQUEZ: Those are really important points that you bring up.
In regard to the role of CXCR4 and its direct interaction with the SDF-1•, we have been able to learn in a series of other parallel experiments over the last two to three years that, actually, the direct interaction between CXCR4 and SDF-1• is not the mechanism whereby the wound healing and wound repair effects are taking place.
And, in fact, although we have not done direct experiments with AMD 3100, or any specific blocker of CXCR4, we have been able to very carefully delineate that the mechanism whereby SDF-1• promotes wound healing actually has to do with changing the profile of surface adhesion molecules on the endothelial cells that are lining the capillaries at the bed of those wounds and on the circulating EPC that then home to that capillary bed.
And as a result of being able to mediate more specific, more direct, more robust interactions between the endothelial cell and certain subpopulations of the bone marrow derived progenitor cells, such as endothelial progenitor cells (EPC), and likely other populations, the pro-angiogenesis and pro-repair effects of SDF-1• are derived. Generally, transplanting autologous fibroblasts into wounds (which is effectively what we do by skin grafts) is not believed to lead to sarcoma risk but we do need to keep in mind that autologous bone marrow derived stem cells may have some theoretical tumor risk (since these are immature cells prior to terminal differentiation). However, to date, several parallel clinical trials with autologous bone marrow derived stem cells in this area of cutaneous wound healing fail to raise concerns of this nature.
